Table 3.
Non-hematological toxicities of PI-88 and docetaxel
| PI-88 (mg/day) |
Docetaxel (mg/m2) |
No courses (patients) |
Fatigue incidence (number of courses) |
Dysgeusia incidence (number of courses) |
Diarrhea incidence (number of courses) |
Nausea incidence (number of courses) |
Emesis incidence (number of courses) |
Dyspepsia incidence (number of courses) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G1 | G2 | G3 | G1 | G2 | G1 | G2 | G1 | G2 | G1 | G2 | G1 | G2 | |||
| 106 | 30 | 3 (6) | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| 140 | 30 | 3 (5) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 190 | 30 | 3 (8) | 2 | 3 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 0 |
| 250 | 30 | 7 (23) | 6 | 1 | 1 | 1 | 10 | 1 | 0 | 2 | 0 | 2 | 0 | 2 | 0 |
| Total | 16 (42) | 16 (38%) | 12 (28.5%) | 6 (14%) | 5 (12%) | 4 (10%) | 4 (10%) | ||||||||
G1–G3 represent National Cancer Institute CTC grades 1–3 (version 2.0). The number of cycles in which each toxicity was observed is indicated in the body of the table